• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬 PD-1/PD-L1 特异性单克隆抗体的开发及犬 T 细胞功能的扩增。

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.

机构信息

Center for Immunology and Infectious Diseases, Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California, Davis, California, United States of America.

Center for Companion Animal Health, Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, California, United States of America.

出版信息

PLoS One. 2020 Jul 2;15(7):e0235518. doi: 10.1371/journal.pone.0235518. eCollection 2020.

DOI:10.1371/journal.pone.0235518
PMID:32614928
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7332054/
Abstract

Interruption of the programmed death 1 (PD-1) / programmed death ligand 1 (PD-L1) pathway is an established and effective therapeutic strategy in human oncology and holds promise for veterinary oncology. We report the generation and characterization of monoclonal antibodies specific for canine PD-1 and PD-L1. Antibodies were initially assessed for their capacity to block the binding of recombinant canine PD-1 to recombinant canine PD-L1 and then ranked based on efficiency of binding as judged by flow cytometry. Selected antibodies were capable of detecting PD-1 and PD-L1 on canine tissues by flow cytometry and Western blot. Anti-PD-L1 worked for immunocytochemistry and anti-PD-1 worked for immunohistochemistry on formalin-fixed paraffin embedded canine tissues, suggesting the usage of this antibody with archived tissues. Additionally, anti-PD-L1 (JC071) revealed significantly increased PD-L1 expression on canine monocytes after stimulation with peptidoglycan or lipopolysaccharide. Together, these antibodies display specificity for the natural canine ligand using a variety of potential diagnostic applications. Importantly, multiple PD-L1-specific antibodies amplified IFN-γ production in a canine peripheral blood mononuclear cells (PBMC) concanavlin A (Con A) stimulation assay, demonstrating functional activity.

摘要

阻断程序性死亡 1(PD-1)/程序性死亡配体 1(PD-L1)通路是人类肿瘤学中一种已确立且有效的治疗策略,并有望应用于兽医肿瘤学。我们报告了用于检测犬 PD-1 和 PD-L1 的单克隆抗体的产生和特性。首先评估了抗体阻断重组犬 PD-1 与重组犬 PD-L1 结合的能力,然后根据流式细胞术判断的结合效率进行排序。选择的抗体能够通过流式细胞术和 Western blot 检测犬组织中的 PD-1 和 PD-L1。免疫细胞化学使用抗 PD-L1(JC071),福尔马林固定石蜡包埋的犬组织的免疫组织化学使用抗 PD-1,这表明该抗体可用于存档组织。此外,抗 PD-L1(JC071)在肽聚糖或脂多糖刺激后,犬单核细胞上的 PD-L1 表达显著增加。总之,这些抗体使用多种潜在的诊断应用显示出对天然犬配体的特异性。重要的是,在犬外周血单核细胞(PBMC)刀豆蛋白 A(Con A)刺激试验中,多种 PD-L1 特异性抗体可扩增 IFN-γ 的产生,证明了其功能活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/9aae9a461981/pone.0235518.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/5bd932fcf4a1/pone.0235518.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/fa313c0e5372/pone.0235518.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/a786d7b5ea6e/pone.0235518.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/0d047c3be62c/pone.0235518.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/6dc5593769ec/pone.0235518.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/6b42c3b5d327/pone.0235518.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/7adfef007fe0/pone.0235518.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/9aae9a461981/pone.0235518.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/5bd932fcf4a1/pone.0235518.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/fa313c0e5372/pone.0235518.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/a786d7b5ea6e/pone.0235518.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/0d047c3be62c/pone.0235518.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/6dc5593769ec/pone.0235518.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/6b42c3b5d327/pone.0235518.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/7adfef007fe0/pone.0235518.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c21d/7332054/9aae9a461981/pone.0235518.g008.jpg

相似文献

1
Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.犬 PD-1/PD-L1 特异性单克隆抗体的开发及犬 T 细胞功能的扩增。
PLoS One. 2020 Jul 2;15(7):e0235518. doi: 10.1371/journal.pone.0235518. eCollection 2020.
2
Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.抗犬PD-1和PD-L1单克隆抗体的研发与特性分析
Vet Immunol Immunopathol. 2018 Apr;198:19-25. doi: 10.1016/j.vetimm.2018.02.007. Epub 2018 Feb 16.
3
Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry .开发和鉴定抗犬 PD-L1 单克隆抗体及其在犬肿瘤组织中的免疫组化表达。
Vet Q. 2023 Dec;43(1):1-9. doi: 10.1080/01652176.2023.2240380.
4
Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs.开发一种体外检测方法,用于筛选犬类程序性死亡受体-1/程序性细胞死亡配体 1 单克隆抗体治疗药物。
Vet Immunol Immunopathol. 2024 Aug;274:110792. doi: 10.1016/j.vetimm.2024.110792. Epub 2024 Jun 13.
5
Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.犬肿瘤细胞上PD-L1的表达以及通过PD-L1阻断增强肿瘤浸润细胞的IFN-γ产生。
PLoS One. 2014 Jun 10;9(6):e98415. doi: 10.1371/journal.pone.0098415. eCollection 2014.
6
PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response.IFN-α/γ 介导的 Stat1 上调抑制抗 HBV T 细胞反应。
PLoS One. 2020 Jul 6;15(7):e0228302. doi: 10.1371/journal.pone.0228302. eCollection 2020.
7
Comparative characterization of two monoclonal antibodies targeting canine PD-1.比较两种针对犬 PD-1 的单克隆抗体的特性。
Front Immunol. 2024 May 8;15:1382576. doi: 10.3389/fimmu.2024.1382576. eCollection 2024.
8
The role of the PD-1/PD-L1 axis in macrophage differentiation and function during pregnancy.PD-1/PD-L1 轴在妊娠期间巨噬细胞分化和功能中的作用。
Hum Reprod. 2019 Jan 1;34(1):25-36. doi: 10.1093/humrep/dey347.
9
An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.一种用于人PD1/PD-L1信号体外生成及功能分析的优化方案。
J Recept Signal Transduct Res. 2018 Feb;38(1):31-36. doi: 10.1080/10799893.2017.1414843. Epub 2017 Dec 18.
10
Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.通过 PD-L1/PD-1 和 Gal-9/TIM-3 通路介导的 NF-κB 活化减少抑制人脂肪来源干细胞对 T 细胞亚群的作用。
Stem Cells Dev. 2018 Sep 1;27(17):1191-1202. doi: 10.1089/scd.2018.0033.

引用本文的文献

1
Characterization of a Potential Therapeutic Anti-Canine PD-1 Single Domain Antibody Produced in Yeast.酵母表达的一种潜在治疗性抗犬PD-1单域抗体的特性分析
Vet Sci. 2025 Jul 8;12(7):649. doi: 10.3390/vetsci12070649.
2
mRNA and protein expression of programmed cell death-ligand-1 on canine mammary gland tumour in dogs of Chiang Mai, Thailand.泰国清迈犬乳腺肿瘤中程序性细胞死亡配体-1的mRNA和蛋白表达
Int J Vet Sci Med. 2025 Apr 3;13(1):1-11. doi: 10.1080/23144599.2025.2483102. eCollection 2025.
3
Discovery and functional characterization of canine PD-L1-targeted antibodies for evaluating antitumor efficacy in a canine osteosarcoma xenograft model.

本文引用的文献

1
Trends in clinical development for PD-1/PD-L1 inhibitors.PD-1/PD-L1抑制剂的临床开发趋势。
Nat Rev Drug Discov. 2020 Mar;19(3):163-164. doi: 10.1038/d41573-019-00182-w.
2
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.去除 N-连接糖基化可增强 PD-L1 的检测,并预测抗 PD-1/PD-L1 治疗效果。
Cancer Cell. 2019 Aug 12;36(2):168-178.e4. doi: 10.1016/j.ccell.2019.06.008. Epub 2019 Jul 18.
3
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.PD-1/PD-Ls 检查点:NK 细胞潜在作用的新见解。
用于评估犬骨肉瘤异种移植模型中抗肿瘤疗效的犬源PD-L1靶向抗体的发现与功能表征。
Sci Rep. 2025 Mar 4;15(1):7574. doi: 10.1038/s41598-025-90770-1.
4
Validation of a PD-1/CD28 chimeric switch receptor to augment CAR-T function in dogs with spontaneous B cell lymphoma.一种用于增强患有自发性B细胞淋巴瘤犬类的CAR-T功能的PD-1/CD28嵌合开关受体的验证
iScience. 2024 Aug 31;27(9):110863. doi: 10.1016/j.isci.2024.110863. eCollection 2024 Sep 20.
5
A Review on Canine and Human Soft Tissue Sarcomas: New Insights on Prognosis Factors and Treatment Measures.犬类和人类软组织肉瘤综述:预后因素与治疗措施的新见解
Vet Sci. 2024 Aug 10;11(8):362. doi: 10.3390/vetsci11080362.
6
A review of CD4 T cell differentiation and diversity in dogs.犬类CD4 T细胞分化与多样性综述。
Vet Immunol Immunopathol. 2024 Sep;275:110816. doi: 10.1016/j.vetimm.2024.110816. Epub 2024 Aug 21.
7
Comparative characterization of two monoclonal antibodies targeting canine PD-1.比较两种针对犬 PD-1 的单克隆抗体的特性。
Front Immunol. 2024 May 8;15:1382576. doi: 10.3389/fimmu.2024.1382576. eCollection 2024.
8
Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.犬源化抗犬程序性死亡1抗体在患有晚期非口腔恶性黑色素瘤实体瘤犬中的概念验证研究。
J Vet Sci. 2024 Jan;25(1):e15. doi: 10.4142/jvs.23144.
9
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs.扩展基于平台的生理药代动力学模型以适用于不同的临床前物种:猫、绵羊和狗的单克隆抗体。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):621-638. doi: 10.1007/s10928-023-09893-5. Epub 2023 Nov 10.
10
Inhibitory checkpoint molecule mRNA expression in canine soft tissue sarcoma.犬软组织肉瘤中抑制性检查点分子mRNA的表达
Vet Comp Oncol. 2023 Dec;21(4):709-716. doi: 10.1111/vco.12934. Epub 2023 Sep 7.
Front Immunol. 2019 Jun 4;10:1242. doi: 10.3389/fimmu.2019.01242. eCollection 2019.
4
A safe and potent anti-CD19 CAR T cell therapy.一种安全有效的抗 CD19 CAR T 细胞疗法。
Nat Med. 2019 Jun;25(6):947-953. doi: 10.1038/s41591-019-0421-7. Epub 2019 Apr 22.
5
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
6
Cellular Immunotherapy of Canine Cancer.犬类癌症的细胞免疫疗法。
Vet Sci. 2018 Dec 6;5(4):100. doi: 10.3390/vetsci5040100.
7
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
8
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
9
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.免疫检查点阻断治疗的基本机制。
Cancer Discov. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16.
10
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.